News
  • Discover
  • Journals
  • Momentum
  • Rankings
  • Local
  • Trending
  • Latest
  • Top Stories
  • Rising
  • Controversial
  • Bubble Gap
  • Log in

Get above the noise

Log in for answers tailored to you — saved chats, your topics, and the full IJR suite.

Log in

IJR News

© IJR AI, Inc.

Privacy PolicyTerms of UseCookie PolicyInvestorsGet the appContact
Live
•Carly Simon Reveals Parkinson's Disease and Facial Cancer•Shanahan Limited Ahead of Melbourne Opener•France Wildfires Threaten Bordeaux, Spread to Spain•Bosa Reacts to Ryan Clark’s ESPN Firing•Romo Is Arrested in Milwaukee for OWI•US-Iran Pause to Resume Talks Amid Tensions•LeBron Signs with 76ers; Player Option Highlight•Black Sea Strife Escalates; India Calls Out Strikes•Paramount-Warner Deal Delayed to 2027 Amid Antitrust Challenges•European Wildfires Trigger Major Evacuations, Emergencies
•Carly Simon Reveals Parkinson's Disease and Facial Cancer•Shanahan Limited Ahead of Melbourne Opener•France Wildfires Threaten Bordeaux, Spread to Spain•Bosa Reacts to Ryan Clark’s ESPN Firing•Romo Is Arrested in Milwaukee for OWI•US-Iran Pause to Resume Talks Amid Tensions•LeBron Signs with 76ers; Player Option Highlight•Black Sea Strife Escalates; India Calls Out Strikes•Paramount-Warner Deal Delayed to 2027 Amid Antitrust Challenges
what's gaining coverage right now
🕹️ Today in the ArcadeWobble Rumble · ⚡ Golden AgePlay →✍️ Voices risingDCNF’s Thomas Phippen Interviews Sen. Marsha Blackburn · Daily Caller News Foundation · most read this weekRead →
AstraZeneca Posts Q2 Beat, Reaffirms 2026 OutlookMarkets

AstraZeneca Posts Q2 Beat, Reaffirms 2026 Outlook

AstraZeneca beat second-quarter profit expectations and reaffirmed its 2026 outlook despite concerns about future growth after a trial setback, as investors await further details on its earnings trajectory. Analysts are mixed but broadly positive, with several buy ratings and a focus on the upcoming Q2 results and oncology-driven revenue, amid a broader market backdrop of cautious trading ahead of earnings.

👤Pascal Soriot
Jul 27, 2026
EU Approves Etcamah in First-Line ER+ Breast CancerEuropean Union

EU Approves Etcamah in First-Line ER+ Breast Cancer

AstraZeneca’s Etcamah (camizestrant) won EU approval to be used with CDK4/6 inhibitors as a first-line treatment for ER-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations, based on SERENA-6 trial results showing a 56% reduction in progression or death. The drug already has approvals in Japan, the UAE, and Saudi Arabia, with U.S. review ongoing and the EU decision highlighting its potential to expand AstraZeneca’s oncology footprint as it targets endocrine-resistant disease.

📍United States🏢European Union
Jul 23, 2026
AstraZeneca India CFO Bhavana Agrawal to resignBusiness Leaders

AstraZeneca India CFO Bhavana Agrawal to resign

AstraZeneca Pharma India said CFO and Whole-Time Director Bhavana Agrawal will resign to take a regional role within the AstraZeneca Group, effective August 31, 2026, with a multi‑week handover and a search for a successor. Regulatory filings confirm the move as part of global realignment, while the company notes strong FY2025-26 growth, including about 33% higher revenue and solid PAT, underscoring ongoing operational resilience.

Jul 21, 2026
From IJR journals·Daily Caller News FoundationRand Paul Introduces Resolution To Hold Fauci In Contempt

More headlines

  • Three Men Killed in Wheathampstead Hertfordshire Two-Vehicle CrashA two-vehicle crash on Cory Wright Way in Wheathampstead involving a silver Vauxhall Astra and a grey BMW 840i killed three men in their 30s to 50s and left the BMW driver seriously injured, with conditions of the victims and ongoing investigations being reported by multiple outlets; police have appealed for witnesses and dash-cam footage as road closures were lifted.5 src · Jul 23, 2026
•European Wildfires Trigger Major Evacuations, Emergencies